

## INFORMAZIONI PERSONALI



CLAUDIA RAVAGLIA

sesso F | data nascita 06/09/1979 | nazionalità Italy

## ESPERIENZE LAVORATIVE

2008

Honorary Clinical Fellow at Royal Brompton Hospital, Sydney Street, London (UK).  
Interstitial Lung Disease Unit. Director: Prof Athol Wells.  
Full registration as medical practitioner, UK, GMC reference number 7018143

2008-2009

Specialista Pneumologo presso San Pier Damiano Hospital (Gruppo Villa Maria), Faenza (RA) – Italy  
UO di Pneumologia e Terapia Intensiva Respiratoria. Director: Dr. Cimino Del Bufalo

2009

Locum Registrar in Respiratory Medicine at Royal Brompton Hospital, London (UK)  
Interstitial Lung Disease Unit. Director: Prof Athol Wells.  
Full registration as medical practitioner, UK, GMC reference number 7018143

2011

Locum Registrar in Respiratory Medicine at Royal Brompton Hospital, London (UK)  
Interstitial Lung Disease Unit. Director: Prof Athol Wells.  
Full registration as medical practitioner, UK, GMC reference number 7018143

From 2009 onwards

Dirigente medico I livello presso UO di Pneumologia. Morgagni Hospital. Forlì (FC) – Italy.  
Director: Prof Venerino Poletti.

9/11/2020

Abilitazione a professore associato in Malattie dell'Apparato Respiratorio  
(settore concorsuale 06/D1, settore scientifico disciplinare MED10)

## ISTRUZIONE E FORMAZIONE

1998

Diploma di Maturità, Liceo Scientifico Severi Faenza (RA), voto 60/60

2004

Laurea in Medicina e Chirurgia, Alma Mater Studiorum Bologna (BO), voto 110/110 lode. Titolo della tesi "La bronchiolite cronica: evoluzione della malattia e correlazioni tra i dati funzionali ventilo-respiratori e radiologici"

2008

Specializzazione in Malattie dell'Apparato Respiratorio, Ospedale S.Orsola-Malpighi Bologna (BO), voto 70/70 lode. Titolo della tesi "Efficacia del trattamento con Ciclofosfamide in gruppi di pazienti con OP e NSIP; risultati dopo sei mesi di trattamento"

## LINGUA/PATENTE

Madre lingua

Italiano

Other language(s)

English

Patente di guida

UNDERSTANDING		SPEAKING		WRITING
Listening	Reading	Spoken interaction	Spoken production	
C2	C2	C2	C2	C2

B

## Produzione scientifica

**I) Thesis Discussion**

"Efficacia del trattamento con ciclofosfamide in gruppi di pazienti con NSIP ed OP/NSIP; risultati dopo 6 mesi di trattamento". 4.10.2008 at Alma Mater Studiorum University of Bologna, Bologna, ITALY. Principal investigator: Claudia Ravaglia. Chair: Prof M. Fabbri, Respiratory Medicine, Alma Mater Studiorum University of Bologna, Bologna – ITALY.

**II) Scientific publications (peer reviewed)**
**IIA. RESEARCH INVESTIGATIONS**

- Doglioni C, Ravaglia C, Chilosi M, Rossi G, Dubini A, Pedica F, Piciocchi S, Vizzuso A, Stella F, Maitan S, Agnoletti V, Puglisi S, Poletti G, Sambri V, Pizzolo G, Bronte V, Wells A, U, Poletti V: Covid-19 Interstitial Pneumonia: Histological and Immunohistochemical Features on Cryobiopsies. *Respiration* 2021. doi: 10.1159/000514822
- Landi L, Ravaglia C, Russo E, Cataleta P, Fusari M, Boschi A, Giannarelli D, Facondini F, Valentini I, Panzini I, Lazzari-Agli L, Bassi P, Marchionni E, Romagnoli R, De Giovanni R, Assirelli M, Baldazzi F, Pieraccini F, Rametta G, Rossi L, Santini L, Valenti I, Cappuzzo F. Blockage of interleukin-1 $\beta$  with canakinumab in patients with Covid-19. *Sci Rep*. 2020 Dec 11;10(1):21775.
- Di Castelnuovo A, Costanzo S, Antinori A, Berselli N, Blandi L, Bonaccio M, Cauda R, Guaraldi G, Menicanti L, Mennuni M, Parruti G, Patti G, Santilli F, Signorelli C, Vergori A, Abete P, Ageno W, Agodi A, Agostoni P, Aiello L, Al Moghazi S, Arboretti R, Astuto M, Aucella F, Barbieri G, Bartoloni A, Bonfanti P, Cacciatore F, Caiano L, Carrozzi L, Cascio A, Ciccullo A, Cingolani A, Cipollone F, Colomba C, Colombo C, Crosta F, Danzi GB, D'Ardes D, de Gaetano Donati K, Di Gennaro F, Di Tano G, D'Offizi G, Fantoni M, Fusco FM, Gentile I, Gianfagna F, Grandone E, Graziani E, Grisafi L, Guarnieri G, Larizza G, Leone A, Maccagni G, Madaro F, Maitan S, Mancarella S, Mapelli M, Maragna R, Marcucci R, Maresca G, Marongiu S, Marotta C, Marra L, Mastroianni F, Mazzitelli M, Mengozzi A, Menichetti F, Meschiari M, Milic J, Minutolo F, Molena B, Montineri A, Mussini C, Musso M, Niola D, Odone A, Olivieri M, Palimodde A, Parisi R, Pasi E, Pesavento R, Petri F, Pinchera B, Poletti V, Ravaglia C, Rognoni A, Rossato M, Rossi M, Sangiovanni V, Sanrocco C, Scorzolini L, Sgariglia R, Simeone PG, Taddei E, Torti C, Vettor R, Vianello A, Vinceti M, Virano A, Vociante L, De Caterina R, Iacoviello L. Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: the Multicenter Italian CORIST Study. *Thromb Haemost*. 2021 Jan 7. doi: 10.1055/a-1347-6070. Online ahead of print.
- Salton F, Confalonieri P, Meduri GU, Santus P, Harari S, Scala R, Lanini S, Vertui V, Oggionni T, Caminati A, Patruno V, Tamburrini M, Scartabellati A, Parati M, Villani M, Radovanovic D, Tomassetti S, Ravaglia C, Poletti V, Vianello A, Gaccione AT, Guidelli L, Raccanelli R, Lucernoni P, Lacedonia D, Foschino Barbaro MP, Centanni S, Mondoni M, davi M, Fantin A, Cao X, Torelli L, Zucchetto A, Montico M, Casarin A, Romagnoli M, Gasparini S, Bonifazi M, D'Agaro P, Marcello A, Licastro D, Ruaro B, Volpe MC, Umberger R, Confalonieri M. *Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia*. *Open Forum Infectious Diseases*, Volume 7, Issue 10, October 2020, ofaa421, <https://doi.org/10.1093/ofid/ofaa421>
- Ambrosini-Spaltro A, Dubini A, Pieri F, Ravaglia C, Delmonte A, Poletti V. *PD-L1 expression in NSCLC: role of cell blocks and concordance between samples*. *Diagn Cytopathol* 2020 October 22; <https://doi.org/10.1002/dc.24646>
- Di Castelnuovo A, Costanzo S, Antinori A, Berselli N, Blandi L, Bonaccio M, Cauda R, Gialluisi A, Guaraldi G, Menicanti L, Mennuni M, Mussinelli R, My I, Parruti G, Patti G, Perlini S, Santilli F, Signorelli C, Stefanini GG, Vergori A, Abete P, Ageno W, Agostoni P, Aiello L, Al Moghazi S, Arboretti R, Aucella F, Barbieri G, Barchitta M, Bartoloni A, Bonfanti P, Cacciatore F, Caiano L, Carrozzi L, Cascio A, Castiglione G, Cianfrone S, Ciccullo A, Cingolani A, Cipollone F, Colomba C, Colombo C, Cozzi O, Crisetti A, Crosta F, Danzi GB, D'Ardes D, de Gaetano Donati K, Di Gennaro F, Di Tano G, D'Offizi G, Fusco FM, Gentile I, Graziani E, Guarnieri G, Larizza G, Leone A, Lio V, Mothanje BL, Maccagni G, Madaro F, Maitan S, Mancarella S, Manuele R, Mapelli M, Maragna R, Marcucci R, Maresca G, Marongiu S, Marotta C, Marra L, Mastroianni F, Mazzitelli M, Mengozzi A, Menichetti F, Meschiari M, Milic J, Minutolo F, Molena B, Mussini C, Musso M, Odone A, Olivieri M, Palimodde A, Pasi E, Pesavento R, Petri F, Pinchera B, Pivato CA, Poletti V, Ravaglia C, Rossato M, Rossi M, Sabena A, Salinaro F, Sangiovanni V, Sanrocco C, Scoppettuolo G, Scorzolini L, Sgariglia R, Simeone PG, Trecarichi EM, Vettor R, Vianello A, Vinceti M, Virano A, Vociante L, Iacoviello L. *RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies*. *Vascular Pharmacology* (2020), <https://doi.org/10.1016/j.vph.2020.106805>
- Di Castelnuovo A, Bonaccio M, Costanzo S, Gialluisi A, Antinori A, Berselli N, Blandi

- L, Bruno R, Cauda R, Guaraldi G, My I, Menicanti L, Parruti G, Patti G, Perlini S, Santilli F, Signorelli C, Stefanini GG, Vergori A, Abdeddaim A, Ageno W, Agodi A, Agostoni P, Aiello L, Al Moghazi S, Aucella F, Barbieri G, Bartoloni A, Bologna C, Bonfanti P, Brancati S, Cacciatore F, Caiano L, Cannata F, Carrozzi L, Cascio A, Cingolani A, Cipollone F, Colomba C, Crisetti A, Crosta F, Danzi GB, D'Ardes D, de Gaetano Donati K, Di Gennaro F, Di Palma G, Di Tano G, Fantoni M, Filippini T, Fioretto P, Fusco FM, Gentile I, Grisafi L, Guarnieri G, Landi F, Larizza G, Leone A, Maccagni G, Maccarella S, Mapelli M, Maragna R, Marcucci R, Maresca G, Marotta C, Marra L, Mastroianni F, Mengozzi A, Menichetti F, Milic J, Murri R, Montineri A, Mussinelli R, Mussini C, Musso M, Odone A, Olivieri M, Pasi E, Petri F, Pinchera B, Pivato CA, Pizzi R, Poletti V, Raffaelli F, Ravaglia C, Righetti G, Rognoni A, Rossato M, Rossi M, Sabena A, Salinaro F, Sangiovanni V, Sanrocco C, Scarafino A, Scorzolini L, Sgariglia R, Simeone PG, Spinoni E, Torti C, Trecarichi EM, Vezzani F, Veronesi G, Vettor R, Vianello A, Vinceti M, De Caterina R, Iacoviello L; COvid-19 RISk and Treatments (CORIST) collaboration. *Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicenter Italian CORIST study*. Nutr Metab Cardiovasc Dis. 2020 Jul 31:S0939-4753(20)30306-9.
- Tomassetti S, Ravaglia C, Wells AU, Cavazza A, Colby TV, Rossi G, Ley B, Ryu JH, Puglisi S, Arcadu A, Marchi M, Sultani F, Martinello S, Donati L, Gurioli C, Gurioli C, Tantalocco P, Hetzel J, Dubini A, Piciucchi S, Klersy C, Lavorini F, Poletti V. *Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study*. Lancet Respir Med. 2020 Aug;8(8):786-794.
- Tomassetti S, Ravaglia C, Wells AU, Cavazza A, Colby TV, Rossi G, Ley B, Ryu JH, Puglisi S, Arcadu A, Marchi M, Sultani F, Martinello S, Donati L, Gurioli C, Gurioli C, Tantalocco P, Hetzel J, Dubini A, Piciucchi S, Klersy C, Lavorini F, Poletti V. *Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study*. Lancet Respir Med. 2020 Aug;8(8):786-794.

- Hetzel J, Wells AU, Costabel U, Colby TV, Walsh SLF, Verschakelen J, Cavazza A, Tomassetti S, Ravaglia C, Böckeler M, Spengler W, Kreuter M, Eberhardt R, Darwiche K, Torrego A, Pajares V, Mucic R, Musterle R, Horger M, Fend F, Warth A, Heußel CP, Piciocchi S, Dubini A, Theegarten D, Franquet T, Lerma E, Poletti V, Häntschel M. *Transbronchial cryobiopsy increases diagnostic confidence in interstitial lung disease: a prospective multicenter trial*. Eur Respir J 2020 Aug 18:1901520.
- COVID-19 RISK and Treatments (CORIST) Collaboratio. *Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study*. Eur J Intern Med 2020 Aug 25: S0953-6205(20)30335-6.
- Ravaglia C, Bosi M, Wells AU, Gurioli C, Gurioli C, Dubini A, Piciocchi S, Puglisi S, Mascetti S, Arcadu A, Tomassetti S, Poletti V. *Idiopathic pulmonary fibrosis: prognostic impact of histologic honeycombing in transbronchial cryobiopsy*. Multidiscip Respir Med 2019; 14:3
- Colella S, Ravaglia C, Massaccesi C, D'Emilio V, Panella G, Fioretti F, Conte EG, Collina G, Pela R, Poletti V. *Does transbronchial lung cryobiopsy give useful information in asthmatic patients?* Multidisciplinary Respiratory Medicine (2019) 14:12
- Sirol Aflah Syazatul S, Piciocchi S, Tomassetti S, Ravaglia C, Dubini A, Poletti V. *Cryobiopsy in the diagnosis of bronchiolitis: a retrospective analysis of twenty-three consecutive patients*. Sci Rep 2020; 10(1):10906.
- Bianchi R, Dubini A, Ascoli S, Ravaglia C, Tomassetti S, Puglisi S, Piciocchi S, Gurioli C, Gurioli C, Fiocca R, Poletti V. *Transbronchial cryobiopsy: an effective tool in the diagnosis of lymphoproliferative disorders of the lung*. ERJ Open Res. 2020; 6: 00260-2019.
- Bosi M, Milioli G, Parrino L, Fanfulla F, Tomassetti S, Melpignano A, Trippi U, Vaudano AE, Ravaglia C, Mascetti S, Poletti V. *Quality of life in idiopathic pulmonary fibrosis: the impact of sleep disordered breathing*. Respir Med 2019; 147: 51-57
- Ravaglia C, Wells AU, Tomassetti S, Gurioli C, Gurioli C, Dubini A, Cavazza A, Colby TV, Piciocchi S, Puglisi S, Bosi M, Poletti V. *Diagnostic yield and risk/benefit analysis of trans-bronchial lung cryobiopsy in diffuse parenchymal lung diseases: a large cohort of 699 patients*. BMC Pulm Med 2019; 19: 16.
- Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Soon Kim D, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Montes Worboys A, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstrong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA. *Resequencing study confirms host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis*. Am J Respir Crit Care Med 2019 Apr 29.
- Kronborg-White S, Ravaglia C, Dubini A, Piciocchi S, Tomassetti S, Bendstrup E, Poletti V. *Cryobiopsies are diagnostic in pleuroparenchymal and airway-centered fibroelastosis*. Respir Res 2018; 19:135
- Bosi M, Milioli G, Fanfulla F, Tomassetti S, Ryu JH, Parrino L, Riccardi S, Melpignano A, Vaudano AE, Ravaglia C, Tantalocco P, Rossi A, Poletti V. *OSA and Prolonged Oxygen Desaturation During Sleep are Strong Predictors of Poor Outcome in IPF*. Lung. 2017 Jul 3.
- Viglietta L, Inchingolo R, Pavano C, Tomassetti S, Piciocchi S, Smargiassi A, Ravaglia C, Dubini A, Gurioli C, Gurioli C, Poletti V. *Ultrasonography for the Diagnosis of Pneumothorax after Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Diseases*. Respiration 2017; 94: 232-236
- Ravaglia C, Wells AU, Tomassetti S, Dubini A, Cavazza A, Piciocchi S, Sverzellati N, Gurioli C, Gurioli C, Costabel U, Tantalocco P, Ryu JH, Chilosi M, Poletti V. *Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Disease: Comparison between Biopsy from 1 Segment and Biopsy from 2 Segments - Diagnostic Yield and*

Complications. Respiration 2017; 93: 285-292

- Ravaglia C, Bonifazi M, Wells AU, Tomassetti S, Gurioli C, Piciocchi S, Dubini A, Tantalocco P, Sanna S, Negri E, Tramacere I, Ventura VA, Cavazza A, Rossi A, Chilosi M, La Vecchia C, Gasparini S, Poletti V. *Safety and Diagnostic Yield of Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Diseases: A Comparative Study versus Video-Assisted Thoracoscopic Lung Biopsy and a Systematic Review of the Literature*. Respiration 2016; 91: 215-27
- Ulivi P, Casoni GL, Foschi G, Scarpi E, Tomassetti S, Romagnoli M, Ravaglia C, Mengozzi M, Zoli W, Poletti V. *MMP-7 and fcDNA serum levels in early NSCLC and idiopathic interstitial pneumonia: preliminary study*. Int J Mol Sci 2013; 14: 24097-112
- Casoni GL, Tomassetti S, Cavazza A, Colby TV, Dubini A, Ryu JH, Carretta E, Tantalocco P, Piciocchi S, Ravaglia C, Gurioli C, Romagnoli M, Gurioli C, Chilosi M, Poletti V. *Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases*. PLoS One 2014; 9: e86716
- Ravaglia C, Tomassetti S, Gurioli C, Piciocchi S, Dubini A, Gurioli C, Casoni GL, Romagnoli M, Carloni A, Tantalocco P, Buccioli M, Chilosi M, Poletti V. *Features and outcome of familial idiopathic pulmonary fibrosis*. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 28-36
- Tomassetti S, Gurioli C, Ryu JH, Decker PA, Ravaglia C, Tantalocco P, Buccioli M, Piciocchi S, Sverzellati N, Dubini A, Gavelli G, Chilosi M, Poletti V. *The impact of lung cancer on survival of idiopathic pulmonary fibrosis*. Chest 2015; 147: 157-164
- Tomassetti S, Wells AU, Costabel U, Cavazza A, Colby TV, Rossi G, Sverzellati N, Carloni A, Carretta E, Buccioli M, Tantalocco P, Ravaglia C, Gurioli C, Dubini A, Piciocchi S, Ryu JH, Poletti V. *Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis*. Am J Respir Crit Care Med 2016; 193: 745-52
- S. Tomassetti, J.H. Ryu, C. Gurioli, Ravaglia C, M. Buccioli, P. Tantalocco, P.A. Decker, A. Cavazza, A. Dubini, V. Agnoletti, C. Gurioli, G.L. Casoni, M. Romagnoli, V. Poletti *The effect of anticoagulant therapy for idiopathic pulmonary fibrosis in real life practice*. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30: 121-127.
- Casoni GL, Ulivi P, Mercatali L, Chilosi M, Tomassetti S, Romagnoli M, Ravaglia C, Gurioli C, Gurioli C, Zoli W, Silvestrini R, Poletti V. *Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis*. Int J Biol Markers 2010; 25 (4): 229-235
- Romagnoli M, Nannini C, Piciocchi S, Girelli F, Gurioli C, Casoni G, Ravaglia C, Tomassetti S, Gurioli C, Gavelli G, Carloni A, Dubini A, Cantini F, Chilosi M, Poletti V. *Idiopathic NSIP: an interstitial lung disease associated with autoimmune disorders?* Eur Respir J 2011; 38 (2): 384-391
- Ravaglia C, Gurioli C, Tomassetti S, Casoni GL, Romagnoli M, Gurioli C, Agnoletti V, Poletti V. *Is medical thoracoscopy efficient in the management of multiloculated and organized thoracic empyema?* Respiration 2012; 84: 219-224
- Ravaglia C, Gurioli C, Casoni G, Romagnoli M, Tomassetti S, Gurioli C, Corso RM, Poletti G, Dubini A, Marinou A, Poletti V. *Diagnostic role of rapid on-site cytologic examination (ROSE) of broncho-alveolar lavage in ALI/ARDS*. Pathologica 2012; 104: 65-69.
- Tomassetti S, Cavazza A, Colby TV, Ryu JH, Nanni O, Scarpi E, Tantalocco P, Buccioli M, Dubini A, Piciocchi S, Ravaglia C, Gurioli C, Casoni GL, Gurioli C, Romagnoli M, Poletti V. *Transbronchial biopsy is useful in predicting UIP pattern*. Respir Res 2012; 13: 96



## Produzione scientifica

## IIB. OTHER PEER REVIEWED PUBLICATIONS (REVIEWS, CASE REPORTS AND CASE SERIES, REPORT OF NEW METHODS, GUIDELINES AND CONSENSUS DOCUMENTS)

- Cazzato S, Omenetti A, Ravaglia C, Poletti V. Lung involvement in monogenic interferonopathies. *Eur Respir Rev*. 2020 Dec 15;29(158):200001.
- Vizzuso A, Piciocchi S, Tortola D, Grosso C, Ravaglia C, Poletti V. *J Single dose of subcutaneous tocilizumab in COVID-pneumonia: CT evidence of lymph nodal and parenchymal response*. *J Med Virol*. 2020 Jul 27.
- Ravaglia C, Poletti V. *Bronchiolitis and bronchiolar disorders*. *Semin Respir Crit Care Med* 2020; 41 (2): 311-332.
- Cavazza A, Colby TV, Dubini A, Tomassetti S, Ravaglia C, Poletti V, Mengoli MC, Tagliavini E, Rossi G. *Transbronchial Cryobiopsy in the Diagnosis of Diffuse Lung Disease*. *Surgical Pathology* 13 (2020) 197–208
- Poletti V, Tomassetti S, Gurioli C, Gurioli C, Ascoli S, Piciocchi S, Dubini A, Ravaglia C, Kronborg-White S. *An HIV patient with visceral enlarged lymph nodes*. *Eur Clin Respir J* 2019; 6: 1591843
- Colella S, Scarlata S, Bonifazi M, Ravaglia C, Naur TMH, Pela R, Clementsen PF, Gasparini S, Poletti V. *Biopsy needles for mediastinal lymph node sampling by endosonography: current knowledge and future perspectives*. *J Thorac Dis* 2018; 10: 6960-6968.
- Bendstrup E, Wuyts W, Alfaro T, Chaudhuri N, Cornelissen R, Kreuter M, Melgaard Nielsen K, Münster AMB, Myllärniemi M, Ravaglia C, Vanuytsel T, Wijnenbeek M. *Nintedanib in Idiopathic Pulmonary Fibrosis: practical Management Recommendations for Potential Adverse Events*. *Respiration* 2018; 13: 1-12
- Hetzel J, Maldonado F, Ravaglia C, Wells AU, Colby TV, Tomassetti S, Ryu JH, Fruchter O, Piciocchi S, Dubini A, Cavazza A, Chilosi M, Sverzellati N, Valeyre D, Leduc D, Walsh SLF, Gasparini S, Hetzel M, Hagmeyer L, Haentschel M, Eberhardt R, Darwiche K, Yarmus LB, Torrego A, Krishna G, Shah PL, Annema JT, Herth FJF, Poletti V. *Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure*. *Respiration* 2018 Jan 9
- Poletti V, Ravaglia C, Dubini A, Piciocchi S, Rossi G, Kronborg-White S, Tomassetti S. *How might transbronchial cryobiopsy improve diagnosis and treatment of diffuse parenchymal lung disease patients?* *Expert Rev Respir Med* 2017; Oct 20
- Johansson KA, Strâmbu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, Richeldi L, Wells AU, Vancheri C, Kreuter M; Erice ILD Working Group. *Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?* *Lancet Respir Med* 2017;5: 591-598
- Tomassetti S, Ravaglia C, Poletti V. *Diffuse parenchymal lung disease*. *Eur Respir Rev* 2017; 26.
- Colella S, Clementsen PF, Gurioli C, Gurioli CH, Ravaglia C, Tomassetti S, Rossi A, Piciocchi S, Dubini A, Poletti V. *Endobronchial-ultrasound needle aspiration and endoscopic ultrasound-fine-needle aspiration in thoracic diseases*. *Pathologica* 2016; 108: 59-79
- Piciocchi S, Dubini A, Tomassetti S, Sanna S, Ravaglia C, Carloni A, Gurioli C, Gurioli C, Colby TV, Poletti V. *Angiosarcoma in the chest: radiologic-pathologic correlation: Case report*. *Medicine (Baltimore)* 2016; 95 (48): e5348.
- Poletti V, Ravaglia C, Tomassetti S. *Transbronchial cryobiopsy in diffuse parenchymal lung diseases*. *Curr Opin Pulm Med* 2016; 22: 289-96
- Poletti V, Ravaglia C, Gurioli C, Piciocchi S, Dubini A, Cavazza A, Chilosi M, Rossi A, Tomassetti S. *Invasive diagnostic techniques in idiopathic interstitial pneumonias*. *Respirology* 2016; 21: 44-50
- Pietrangeli V, Piciocchi S, Tomassetti S, Ravaglia C, Gurioli C, Gurioli Ch, Cavazza A, Dubini A, Poletti V. *Diffuse Neuroendocrine Hyperplasia with Obliterative Bronchiolitis and Usual Interstitial Pneumonia: An Unusual "Headcheese Pattern" with Nodules*. *Lung* 2015; 193: 1051-1054
- Poletti V, Gurioli C, Piciocchi S, Rossi A, Ravaglia C, Dubini A, Ascoli S, Casoni GL. *Intravascular large B cell lymphoma presenting in the lung: the diagnostic value of transbronchial cryobiopsy*. *Sarcoidosis Vasc Diffuse Lung Dis* 2015; 31: 354-358
- Ravaglia C, Poletti V. *Recent advances in the management of acute bronchiolitis*. *F1000 Prime Rep* 2014; 6: 103. eCollection 2014. Review.
- Piciocchi S, Dubini A, Tomassetti S, Casoni G, Ravaglia C, Poletti V. *A Case of Amiodarone-induced Acute Fibrinous and Organizing Pneumonia Mimicking Mesothelioma*. *Am J Respir Crit Care Med* 2015; 191: 104-106
- Poletti V, Ravaglia C, Tomassetti S. *Pirfenidone for the treatment of idiopathic pulmonary fibrosis*. *Expert Rev Respir Med* 2014; 8: 539-545
- Poletti V, Ravaglia C, Tomassetti S, Gurioli C, Casoni G, Ascoli S, Dubini A, Piciocchi

S, Chilosi M. *Lymphoproliferative lung disorders: clinicopathological aspects*. Eur Respir Rev 2013; 22: 427-36

- Poletti V, Ravaglia C, Buccioli M, Tantalocco P, Piciucchi S, Dubini A, Carloni A, Chilosi M, Tomassetti S. *Idiopathic pulmonary fibrosis: diagnosis and prognostic evaluation*. Respiration 2013; 86 (1): 5-12
- Ravaglia C, Gurioli C, Casoni GL, Asioli S, Poletti V. *Fever, splenomegaly and lymphopenia in sarcoidosis. Visceral leishmaniasis*. Thorax 2013; 68 (5): 496-497
- Gurioli C, Ravaglia C, Romagnoli M, Casoni G, Tomassetti S, Nanni O, Poletti V. *EBUS-TBNA in mediastinal/hilar lymphadenopathies and/or masses: an Italian case series*. Clin Respir J 2012; 6: 3-8.
- Tomassetti S, Carloni A, Chilosi M, Maffè A, Ungari S, Sverzellati N, Gurioli C, Casoni G, Romagnoli M, Gurioli C, Ravaglia C, Poletti V. *Pulmonary features of Birt-Hogg-Dubé syndrome: cystic lesions and pulmonary histiocytoma*. Respir Med 2011; 105: 768-774.
- Poletti V, Casoni G, Ravaglia C, Romagnoli M, Tomassetti S. *Bronchoalveolar lavage. Technical notes*. Monaldi Arch Chest Dis 2011;75 (1): 42-43
- Ravaglia C, Poletti G, Gurioli C, Casoni GL, Dubini A, Re G, Poletti V. *Sweet's syndrome associated with myelogenous leukemia and pulmonary involvement*. Monaldi Arch Chest Dis 2011; 75 (2): 149-150.
- Gurioli C, Casoni GL, Gurioli C, Tomassetti S, Romagnoli M, Ravaglia C, Poletti V. *Endobronchial ultrasound in Dieulafoy's disease of the bronchus: an additional application of EBUS*. Monaldi Arch Chest Dis 2010; 73 (4): 166-168
- Casoni GL, Tomassetti S, Coffa A, Ravaglia C, Poletti V. *Negative pressure pulmonary hemorrhage induced by a candy*. Am J Emerg Med 2010; 28: 112



## Produzione scientifica

## IIC. LETTERS TO THE EDITOR/CORRESPONDENCE

- Poletti V, Tomassetti S, Ravaglia C. Time to Trust Transbronchial Cryobiopsy in Identification of UIP Pattern? Am J Respir Crit Care Med. 2021 Jan 27. doi: 10.1164/rccm.202012-4382ED.
- Piciucchi S, Ravaglia C, Vizzuso Am Bertocco M, Poletti V. *Reversibility of venous dilatation and parenchymal changes density in Sars-Cov-2 pneumonia: toward the definition of a peculiar pattern* Pulmonology. 2020 Nov 16 doi: 10.1016/j.pulmoe.2020.10.010
- Ravaglia C. *Hypersensitivity pneumonitis: Need for a better diagnostic evaluation.* Pulmonol 2020 Feb 1: S2531-0437(20)30002-7
- Poletti V, Ravaglia C. Methodological issues are important in cannabinoids determination in bronchoalveolar lavage. Clin Chem Lab Med 2019 Jan 30
- Ravaglia C, Tomassetti S, Poletti V. New Idiopathic Pulmonary Fibrosis Guidelines: Are Cryobiopsy and Surgery Competitive in Clinical Practice? Am J Respir Crit Care Med 2018; Dec 19.
- Poletti V, Tomassetti S, Ravaglia C. Idiopathic Pulmonary Fibrosis. N Engl J Med 2018; 379: 797
- Piciucchi S, Tomassetti S, Ravaglia C, Gurioli C, Gurioli C, Dubini A, Carloni A, Chilosi M, Colby TV, Poletti V. *From "traction bronchiectasis" to honeycombing in idiopathic pulmonary fibrosis: A spectrum of bronchiolar remodeling also in radiology?* BMC Pulm Med 2016; 16: 87
- Ravaglia C, Gurioli C, Casoni GL, Romagnoli M, Tomassetti S, Gurioli C, Dubini A, Poletti V. *Sarcoid-like lesion is a frequent benign cause of lymphadenopathy in neoplastic patients.* Eur Respir J. 2013; 41 (3): 754-755
- Ravaglia C, Tomassetti S, Gurioli C, Bucciolini M, Tantalocco P, Derni S, Maltoni M, Poletti. *Palliative medicine and end-of-life care in idiopathic pulmonary fibrosis.* J Palliat Med. 2013; 16 (4): 339.
- Casoni GL, Gurioli C, Ravaglia C, Gurioli C, Poletti V. *Endobronchial ultrasound-guided transbronchial needle aspiration: one defect away from perfect.* Chest 2011; 140 (1): 265; author reply 265-266

## IID. BOOKS/TEXTBOOKS FOR THE MEDICAL OR SCIENTIFIC COMMUNITY

-*Malattie dell'apparato respiratorio*. Chapters: "Versamenti pleurici" (Belmonte G, Mistè G, Ravaglia C); "Malattie dell'interstizio polmonare" (Belmonte G, Ravaglia C, Gaddi P); "Asma bronchiale" (Belmonte G, Piccari L, Ravaglia C). CLUEB 2007.

-*Ecoendoscopia toracica*. Chapter: "Citologia nelle patologie polmonari" (Poletti V, Poletti G, Chilosi M, Murer B, Ravaglia C). Edizioni Minerva Medica 2014.

-*Interventions in Pulmonary Medicine*. Chapter: "Cryotherapy: Application in the Airways" (Colella S, Ravaglia C, Tomassetti S, Gurioli C, Gurioli C, Poletti V). Díaz-Jimenez J., Rodriguez A. (eds) Springer, Cham (2018)

-*Transbronchial Cryobiopsy in Diffuse Parenchymal Lung Disease*. Chapters: "Clinical meaning of transbronchial cryobiopsy", "Complications", "Chronic HP (clinical case)". Springer Book, 2018.

## IIE. RESEARCH PUBLICATIONS WITHOUT NAMED AUTHORSHIP

-Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johansson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium (Ravaglia C cited in the Acknowledgments section). *Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.* Eur Respir J 2017 Aug 31; 50 (2). DOI: 10.1183/13993003.00936-2017. Print 2017 Aug. [COLLABORATOR]

## III) Non-peer reviewed publications

- Ravaglia C. *"Aspetti clinici ed epidemiologici delle interstiziopatie polmonari nella popolazione femminile"*. Rassegna di Patologia dell'Apparato Respiratorio. Fascicolo 6/2017. Serie "Medicina di genere in Pneumologia"
- Tomassetti S, Ravaglia C, Gurioli C, Chiappalone G, Poletti V. *"Prognostic assessment in IPF"*. Shortness of Breath, 2015
- Ravaglia C, Gurioli C, Ascoli S, Dubini A, Piciucchi S, Poletti V. *"Un polmone ematologico"*. Rassegna di Patologia dell'Apparato Respiratorio. Fascicolo 6/2014

- Ravaglia C, Tomassetti S. *"Il pattern reticolare"*. Rassegna di Patologia dell'Apparato Respiratorio. Fascicolo 4/2014. Serie: Flow-chart diagnostiche nelle pneumopatie infiltrative
- S Tomassetti, JH. Ryu, G Casoni, C Gurioli, Ravaglia C, M Buccioli, P Tantalocco, C. Gurioli, M Romagnoli, V Poletti. *Revisione critica delle Linee Guida ATS/ERS sulla fibrosi polmonare idiopatica (IPF). Critical revision of ATS / ERS Guidelines on idiopathic pulmonary fibrosis (IPF)*. Rassegna di Patologia dell'Apparato Respiratorio 2013; 28: 74-89

## Società scientifiche

- ERS member (European Respiratory Society) and ERS study-groups member: 1) Assembly 12.01 (Idiopathic Interstitial Pneumonias); 2) Assembly 12.03 (Sarcoidosis and other Granulomatous ILD/DPLP); Assembly 14.01 (Interventional Pulmonology)
- Member of ERS (European Respiratory Society) College of experts and Reviewer of ERS Clinical Training Fellowship
- AIPO member (Associazione Italiana Pneumologi Ospedalieri)
- “Pneumopatie infiltrative diffuse e patologia del piccolo circolo” AIPO study group coordinator (from 2018 onwards).
- ERN (European Reference Network) member
- EABIP and WABIP member (da novembre 2019)

## Trial di ricerca

**Sponsored clinical trials**

- 2009: Sub-investigator in PIPF-012 study - NCT00287729 (Open-Label Study). Purpose: to assess the efficacy of treatment with Pirfenidone 2403 mg/day compared with placebo in patients with Idiopathic Pulmonary Fibrosis and to assess the safety of treatment with Pirfenidone 2403 mg/day compared with placebo in patients with IPF.
- 2009: Sub-investigator in BUILD-3 study NCT00391443 (prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study). Primary objective: to demonstrate that Bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis.
- 2009: Sub-investigator in BUILD-3-open label study (Open Label Extension Study in patients with Idiopathic Pulmonary Fibrosis who completed Protocol AC-052-321/BUILD3)
- 2010: Sub-investigator in ARTEMIS-IPF study - NCT00768300 (Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in Idiopathic Pulmonary Fibrosis). \* We were audited and successfully completed PPD audit on 16-17 November 2010.
- 2010: Sub-investigator in ARTEMIS-PH study - NCT00879229 (Phase 3, randomized, double-blind, placebo-controlled, multicenter study). Purpose: to compare the efficacy and safety of ambrisentan to placebo in subjects with pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis.
- 2011-2012: Sub-investigator in Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis patients study - NCT01335464 (prospective, randomized study). Purpose: to investigate and confirm the efficacy and safety of BIBF 1120 at a high dose in treating patients with Idiopathic Pulmonary Fibrosis, compared with placebo.
- From 2012 onwards: Sub-investigator in “An open label extension trial of the long term safety of oral BIBF 1120 patients with IPF”. Purpose: to assess the long-term safety of BIBF 1120 treatment in patients with IPF who have completed one year treatment and the follow-up period in the phase III trials 1199.32.
- 2013: Sub-investigator in Efficacy and Safety of GS-6624 in subjects with Idiopathic Pulmonary Fibrosis (RAINIER) GS-US-322-0207
- From 2014 onwards: Sub-investigator in “Efficacy and Safety of LEBRIKIZUMAB in patients with IPF” - GB28547 (phase II, randomized, double-blind, placebo controlled study). Purpose: to assess the efficacy and safety of Lebrikizumab in IPF.
- 2014-2016: Sub-Investigator in PASSPORT study (Post-Authorisation prospective observational Registry). Purpose: to evaluate long term safety profile of Pirfenidone in real world setting in patients with Idiopathic Pulmonary Fibrosis and to monitor for any unknown or potential risks of treatment with Esbriet.
- From 2016 onwards: Sub-investigator in Fibronet study - 1199.262 (Idiopathic Pulmonary Fibrosis Italian Observational Study - Boehringer Ingelheim). Purpose: to evaluate characteristics, management and clinical course of patients with Idiopathic Pulmonary Fibrosis as treated under real-world in Italian Pulmonary Centers, in terms of symptoms, lung function and exercise tolerance during 12 months of observation.

- From 2016 onwards: Sub-investigator in MA29957 study: "A phase IIb, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of Sildenafil added to Pirfenidone in patients with advanced IPF and intermediate or high probability of group 3 pulmonary hypertension".
- From 2017 onwards: Sub-investigator in BI 1199.247 study - NCT02999178: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
- From 2017 onwards: Sub-investigator in MA39189 study - NCT03099187 "A phase III Study of Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease"
- From 2016 onwards: Sub-investigator in BIBF 1199.36 study. "A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib co-administered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment" (INSTAGE)
- From 2018 onwards: Principal investigator in "Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients with Idiopathic Pulmonary Fibrosis - CVAY736X2207"
- From 2018 onwards: sub-investigator in "Studio randomizzato, in doppio cieco, controllato con placebo per valutare l'efficacia e la sicurezza di BG00011 in pazienti affetti da fibrosi polmonare idiopatica" - Biogen 203PF203
- From 2020 onwards: Principal investigator (PI) in MA39189 study - NCT03099187 "A phase III Study of Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease"
- From 2020 onwards: Principal investigator (PI) in MA29957 study: "A phase IIb, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of Sildenafil added to Pirfenidone in patients with advanced IPF and intermediate or high probability of group 3 pulmonary hypertension".
- From 2020 onwards: Principal investigator (PI) of Galactic1 – codice Eudract 2018 002664-73. A randomized double-blind multicenter parallel placebo-controlled phase 2b study in subjects with Idiopathic Pulmonary Fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin 3-inhibitor administered via a dry powder inhaler over 52 weeks
- From 2020 onwards: Principal investigator (PI) on BI 1199.248: An open-label extension trial of the long-term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
- From March 2020 onwards: Principal investigator (PI) on TOCIVID-19 (multicentrico su efficacia e sicurezza di tocilizumab nel trattamento di pazienti affetti da polmonite da COVID-19). *Promotore:* Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale –Napoli
- From March 2020 onwards: Principal investigator (PI) on TOCISCOV (osservazionale sull'impiego del tocilizumab somministrato per via sottocutanea nel trattamento dei pazienti con polmonite da COVID-19). *Promotore:* AUSL Romagna

#### **Non-sponsored research projects**

- 2010: Sub-investigator in GenPhenReSa (Genotype Phenotype Relationship in Sarcoidosis)
- 2011: Principal investigator in "Is Medical Thoracoscopy indicated in the management of Multiloculated and Organized Thoracic Empyema?" (retrospective study). Approved Ethics Committee: 05/09/2011 Nr. 3386/2011. Published in Respiration 2012.
- 2013: Principal investigator in "Pazienti affetti da fibrosi polmonare idiopatica familiare e sporadica; caratteristiche e andamento clinico" (retrospective observational study). Approved Ethics Committee: 18/12/2013 Nr. 0068495. Published 2014
- 2018 sub-investigator in "Saggio Diasorin LIAISON®XL Quantiferon Gold Plus" – PROT. 648.003
- principal investigator in the research project "Clinical meaning of interstitial pneumonia with autoimmune features in Idiopathic Pulmonary Fibrosis" (observational study). Approved Ethics Committee: 2/1/2020 Nr. 30/2020 I.5/284.
- Principal Investigator (PI) in the multicentre research project: Immunovid (Valutazione della risposta immunitaria in pazienti affetti da COVID-19). *Promotore:* Azienda Ospedaliera Universitaria Integrata Verona – Dipartimento di Medicina, sezione di Immunologia, Università di Verona.
- Principal investigator (PI) in the research study "THORACOSCOPY: Valutazione dell'efficacia della toracosopia medica nel trattamento dell'empima pleurico". *Promotore:* Azienda Usl della Romagna. Approved Ethics Committee: Prot. 6448/2020 I.5/140
- Principal investigator (PI) in the research study "CRYOPROBE: Valutazione della resa diagnostica della criobiopsia transbronchiale nella diagnosi delle pneumopatie infiltrative

diffuse: sonde 1,7 e 1,9 mm". *Promotore*: Azienda Usl della Romagna. Approved Ethics Committee: Prot. 7992/2020 I.5/245

## Riviste scientifiche

### Reviewer activities:

1. Sarcoidosis Vasculitis and Diffuse Lung Diseases
2. Respiration
3. Rassegna di Patologia dell'Apparato Respiratorio
4. Therapeutic Advances in Respiratory Disease 2016 (12 Sep 2016 – 7 Oct 2017)
5. ERJ Open Research (from 15 May 2014 onwards)
6. Lancet Respiratory
7. European Respiratory Review
8. Journal of Thoracic Disease (from July 2018 onwards)
9. Pediatric Allergy, Immunology, and Pulmonology (from July 2019 onwards)
10. Pulmonology (from June 2019 onwards)
11. European Respiratory Journal (from 20 July 2019 onwards)
12. Breath (ERS) from 8 August 2019 onwards
13. Respirology Case Reports from 3 August 2019 onwards

### Editorial activities:

1. From 2016 onwards ERJ Open Research – Associated Editor
2. 2010-2016 F1000Prime Associate Faculty Member
3. From 2019 onwards Editor in Chief for "Sarcoidosis Vasculitis and Diffuse Lung Diseases"
4. From March 2020 until December 2021 member of Editorial Board of *Respiration*
5. From October 2020 member of Editorial Board of *BMC Pulmonary Medicine*

## Ruoli in organi istituzionali

Coordinator 2018-2019 of the AIPO (= Associazione Italiana Pneumologi Ospedalieri) study group "Diffuse Infiltrative Pneumopathies and Pulmonary Artery Pathology"

Reviewer of ERS Clinical Training Fellowship from April 2019 onwards

## Consulente per aziende farmaceutiche

- 1) Boeringher-Inghelheim:
  - Interstitial Lung Disease (ILD): *Expert Centre Programme* (Munich, Feb 2017)
  - Advisory Board "Recommendations on nintedanib in IPF" (Frankfurt, Jul 2017)
  - Scientific Exchange Meeting, Gestione multidisciplinare del paziente con IPF (Milan, Nov 2016)
  - Advisory Board "Anticoagulant use and bleeding risk during Nintedanib treatment" (Webinar, Dicembre 2020)
- 2) Novartis: "Progetto miglia – Miglioramento degli interventi sull'asma" (Forlì, May 2018)

## Convegni: moderatore, relatore, comitato scientifico/organizzativo

### Speaker at National Conferences

- XXI Congresso Nazionale della Pneumologia (SIP = Società Italiana di Pneumologia). Formato Webinar. 12.12.2020. Relazione: "La biopsia e il team multidisciplinare rimangono i cardini nella diagnosi di fibrosi polmonare"
- Corso ECM FAD "pneumopatie fibrosanti, discussione interattiva tra esperti". Seminario organizzato in formato webinar. Date: 25 settembre 2020, 23 ottobre 2020, 20 November 2020
- Conference: Interactive Lung days. Treatment of IPF: from clinical trials to real life data. Presentation "Anticoagulant use and bleeding risk during Nintedanib treatment" 22 October 2020.
- Conference "Pneumopatie fibrosanti: discussione tra esperti". Forlì, online dal 6.3.2020 al 29.5.2020.

- Conference: "Medicina di genere e ...". Rimini, 25.1.2020. Presentation: "*Interstiziopatie polmonari*"
- Conference: Forum Giovani Pneumologi. Florence, 13/11/2019. Presentation: "*I trial randomizzati: come interpretarli e come crearne uno*".
- Conference: Pneumopatie infiltrative diffuse – L'importanza di un approccio multidisciplinare e standardizzato. Ancona, 20-21/9/2019. Presentation1: "Polmonite da ipersensibilità o triggered-IPF?" Presentation2: "Discussione multidisciplinare di casi clinici"
- Conference: Corso teorico-pratico PID Pneumopatie Infiltrative Diffuse. Forlì, 25-27/6/2019. Presentation: "*polmonite interstiziale non-specifica*".
- Conference: Corso teorico-pratico PID Pneumopatie Infiltrative Diffuse. Forlì, 25-27/6/2019. Presentation: "*discussione casi clinici*".
- Conference: Il paziente al centro. Forlì, 8/3/2019. Presentation: "*La terapia della IPF: punti fermi e nuove terapie*"
- Conference: Il NET – Percorsi formativi di ricerca, di presa in carico e trattamento del paziente con Asma scarsamente controllato e/o grave. Forlì, 13/10/2018. Presentation: "*Dimensione, Fisiopatologia e clinica dell'asma bronchiale*"
- Conference: Corso teorico-pratico PID Pneumopatie Infiltrative Diffuse. Forlì, 26-28/6/2018. Presentation: "*Discussione di casi clinici*".
- Conference: Corso teorico-pratico PID Pneumopatie Infiltrative Diffuse. Forlì, 26-28/6/2018. Presentation: "*NSIP*"
- Conference: Spring Mediterranean Seminars 2018. Siracusa, 26/4/2018. Presentation: "*Update dei criteri diagnostici dell'IPF e ricadute terapeutiche*".
- Conference: Respirare e comunicare: cosa dobbiamo ancora imparare. Forlì, 15-16/3/2018. Presentation: "*IPF-early: quando trattare?*"
- Conference: Respirare e comunicare: cosa dobbiamo ancora imparare. Forlì, 15-16/3/2018. Presentation: "*Diagnosi della IPF, le nuove linee guida internazionali*".
- Conference: Il futuro è nell'aria – III Edizione. Presentation: "*Il futuro è nell'asma*". Forlì, 9/3/2018.
- Conference: EuroX 5. Bolzano, 3-4/3/2018. Presentation: "*La relazione fra immunologia e polmone*"
- Conference: IPF & Friends. Fibrosi polmonare idiopatica. Presentation: "come si costruisce una clinica sulle PID". Forlì, 21-22/2/2018
- Conference: IPF & Friends. Fibrosi polmonare idiopatica. Presentation: "*Team multidisciplinare al lavoro*". Forlì, 21-22/2/2018
- Conference: VII Convegno regionale dei giovani pneumologi. Parma, 1/12/2017. Presentation: "*Presentazione casi clinici. Pneumologia interventistica*".
- Conference: IPF in practice. Personalizzare l'algoritmo terapeutico. Ravenna, 9-10/11/2017. Presentation: "*Comorbidità e diversi fenotipi*".
- Conference: La criobiopsia nella patologia polmonare parenchimale diffusa. Genova, 14/10/2017. Presentation: "*Resa diagnostica e complicanze della criobiopsia polmonare*".
- Conference: Corso Pneumopatie infiltrative diffuse. Forlì, 20-22/6/2017. Presentation: "*Pneumopatie cistiche diffuse*".



- Conference: Corso Pneumopatie infiltrative diffuse. Forlì, 20-22/6/2017. Presentation: "Discussione dei casi clinici"
- Conference: XLIV Congresso Nazionale AIPO – Congresso Nazionale FIP "Progresso e innovazione tecnologica in pneumologia". Bologna, 10-13/6/2017. Presentation: "NSIP e HP cronica: mito o realtà?"
- Conference: AIR meeting Italia. Bologna, 31/3/2017-1/4/2017. Presentation: "*workshop di pratica clinica: AIR clinical challenge*".
- Conference: Il rinforzo della trama. Forlimpopoli, 12/3/2017. Presentation: "*Presentazione progetti di ricerca passati e futuri*".
- Conference: Il rinforzo della trama. Forlimpopoli, 12/3/2017. Presentation: "*Procedure diagnostiche invasive nelle interstiziopatie*".
- Conference: Seminario IPF & friends. Forlì, 14-16/2/2017. Presentation: "*Come organizzare una unità di ILDs*".
- Conference: Seminario IPF & friends. Forlì, 14-16/2/2017. Presentation: "*Il team multidisciplinare al lavoro*".
- Conference: Cure palliative nel malato respiratorio. Milano, 13-14/1/2017. Presentation: "*Interstiziopatie polmonari*".
- Conference: Meet the Expert in IPF. Forlì, 21/10/2016. Presentation: "*La diagnosi di IPF e la centralità del team multidisciplinare*".
- Conference: Meet the Expert in IPF. Forlì, 21/10/2016. Presentation: "*Stars and Black Holes: successi e problematiche irrisolte dei centri di riferimento. Modelli e risultati organizzativi dei centri e problematiche gestionali*".
- Conference: Corso teorico-pratico Il lavaggio broncoalveolare (BAL): an Update. Mestre; 21/9/2016. Presentation: "*Principali indicazioni*".
- Conference: Corso teorico-pratico Il lavaggio broncoalveolare (BAL): an Update. Mestre; 21/9/2016. Presentation: "*La processazione del BAL (Quanti campioni? Quanti destinatari?)*".
- Conference: Pneumopatie diffuse infiltrative. Forlì; 7-9/6/2016. Presentation: "*Polmonite in via di organizzazione*".
- Conference: Pneumopatie diffuse infiltrative. Forlì; 7-9/6/2016. Presentation: "*Discussione casi clinici*".
- Conference: In Hospital meeting IPF: Excellence. Forlì; 3-4/5/2016. Presentation: "*Patogenesi della IPF*".
- Conference: In Hospital meeting IPF: Excellence. Forlì; 3-4/5/2016. Presentation: "*Discussione casi clinici: la discussione multidisciplinare*".
- Conference: In Hospital meeting IPF: Excellence. Forlì; 24-25/5/2016. Presentation: "*L'IPF a 360°. Patogenesi, clinica e terapia – discussione multidisciplinare di casi clinici*".
- Conference: V post graduate course: le pneumopatie interstiziali diffuse – Gubbio 28-30/4/ 2016. Presentation: "*BPCO e dintorni*".
- Conference: Corso Fibrosi polmonare idiopatica. Forlì 9-11/2/2016. Presentation: "*Discussione interattiva casi clinici su quadri di fibrosi polmonare idiopatica e dintorni*".
- Conference: Corso Fibrosi polmonare idiopatica. Forlì 9-11/2/2016. Presentation: "NSIP"

- Conference: XLIII Congresso Nazionale AIPO – Congresso Nazionale FIP “Qualità e Sostenibilità: le sfide per la pneumologia”. Napoli 11-14/11/2015. Presentation: “*Il paziente ematologico: una sfida difficile*”
- Conference: IV° post graduate course: le pneumopatie interstiziali diffuse (PID). Conoscere per riconoscere. Gubbio 23-25/10/2015. Presentation: “*Le braci: connettiviti e polmone. Presentazione di n.3 casi clinici*”.
- Conference: Corso ECM Confidence – Comunicazione nella Fibrosi Polmonare Idiopatica. Trieste; 19/10/2015. Presentation: *2 casi clinici su “Criticità comunicative”*.
- Conference: La diagnosi multidisciplinare e le scelte terapeutiche delle pneumopatie infiltrative diffuse (IPD) e della fibrosi polmonare idiopatica (IPF). Firenze; 2/10/2015. Presentation: “*Discussione casi clinici*”
- Conference: Pneumopatie infiltrative diffuse. Forlì; 15-17/6/2015. Presentation: “*Discussione casi clinici*”.
- Conference: Pneumopatie infiltrative diffuse. Forlì; 15-17/6/2015. Presentation2: “*Polmonite in via di organizzazione*”
- Conference: 8° congresso di T.M.O Diagnostica e Terapia delle Micosi Opportunistiche. Genova 25-26/6/2015. Presentation: “*Funghi filamentosi e BPCO*”
- Conference: Aggiornamenti in pneumologia: asma ed overlap ASMA/BPCO, Fibrosi Polmonare Idiopatica e Pneumopatie Diffuse Infiltrative. Presentation: “*Pneumopatie infiltrative diffuse: new entries*”. Assisi; 7-8/6/2014

#### Speaker at international conferences (English)

- 36<sup>th</sup> Pulmonology congress: 13 November 2020. Presentation: “Transbronchial cryobiopsy in diffuse lung diseases: do we have enough evidence to dismiss surgical lung biopsy”
- Conference: PNEUMOTRIESTE (COURSE HELD AS LIVE WEBINAR VIA MULTIMEDIA PLATFORM) 5-7-October 2020. Presentation 1 “Sarcoidosis Management”; Presentation 2: “Pulmonary complications of oncologic drugs”
- Conference: IPF & friends. Presentation: Clinical Picture IPF. Forlì, 29-30 September 2020
- Conference: Tranbronchial cryobiopsy in diffuse parenchymal lung disease – 7<sup>th</sup> Edition (COURSE HELD AS LIVE WEBINAR VIA MULTIMEDIA PLATFORM). Presentation: “*IPF and progressive fibrosing ILDs: treatment update*”. 18/09/2020
- Conference. ERS (European Respiratory Society) Conference 2020. Presentation: “Transbronchial cryobiopsy in diffuse parenchymal lung diseases” – Expert view session. Virtual 5-9/9/20.
- Conference. ERS (European Respiratory Society) Conference 2020. Oral Presentation: “Morphological and immunophenotypical features of lung tissue in early phase of COVID-19”. Virtual 5-9/9/20.
- Conference. ERS (European Respiratory Society) Conference 2020. Presentation: “Diagnostic procedures in ICU: bronchoscopy and BAL or tissue?” – Hot Topic session. Virtual 5-9/9/20.
- Conference. ERS (European Respiratory Society) Conference 2020. Presentation: “Invasive approaches in the diagnosis of ILD” – State of the art session. Virtual 5-9/9/20.

- Conference: AIR2019. Presentation: “*New diagnostic tools*”. Malmö, 15-16/11/2019
- Conference. ERS (European Respiratory Society) Conference 2019. Presentation: “Transbronchial lung cryobiopsy in the diagnosis of ILDs”. Madrid 28/9/2019.
- Conference: IPF & friends. Presentation: “*Best clinical practice*”. Forlì, 19-20/2/2019.
- Conference: Transbronchial cryobiopsy in diffuse parenchymal lung disease (a course for pathologists). Presentation: “*Slide Seminar: UIP & neighbours*”. Milano, 1-2/10/2018.
- Conference: Transbronchial cryobiopsy in diffuse parenchymal lung disease (a course for pathologists). Presentation: “*Multidisciplinary team at work*”. Milan 1-2/10/ 2018.
- Conference: Transbronchial cryobiopsy in diffuse parenchymal lung disease – 5th Edition. Presentation: “*Multidisciplinary team at work: cases discussion – 5th session*”. Ravenna; 26-27/9/2018.
- Conference: Transbronchial cryobiopsy in diffuse parenchymal lung disease – 5th Edition. Presentation: “*cryo-TBB side effects and prevention*”. Ravenna; 26-27/9/2018.
- Conference: Transbronchial cryobiopsy in diffuse parenchymal lung disease – 5th Edition. Presentation: “*Multidisciplinary team at work: cases discussion – 12th session*”. Ravenna; 26-27/9/2018.
- Conference: ERS (European Respiratory Society) Conference 2018. Presentation: “Challenging clinical cases: acute respiratory failure 7 years after monolateral lung transplant for COPD. Paris; 18/9/2018.
- Conference: WASOG 2018. Presentation: “BAL: does it still have a major role in ILD diagnosis?”. Crete 7-9/6/2018
- Conference: The pathogenesis of COPD and IPF: distinct horns of the same devil? International workshop. Presentation: “Chronic hypersensitivity pneumonitis: a real entity?”. Firenze 3-5/5/2018.
- Conference: ERS course – Diffuse parenchymal lung diseases (PneumoTrieste). Presentation: “Clinical cases”. Trieste; 17/4/2018
- Conference: 7th Oporto Diffuse Lung Diseases Symposium (endorsed by ERS). Presentation: “The lung in the autoimmune scenery: relevance and assessment”. Porto 23/24/3/2018.
- Conference: 7th Oporto Diffuse Lung Diseases Symposium (endorsed by ERS). Presentation: “Interstitial Pneumonia with Autoimmune Features. where are we?” Porto 23/24/3/2018.
- Conference: Transbronchial cryobiopsy in diffuse parenchymal lung diseases. Presentation: “Update: treatment of IPF”. Peschiera del Garda; 18-19/12/2017.
- Conference: Transbronchial cryobiopsy in diffuse parenchymal lung diseases. Presentation: “Multidisciplinary team at work”. Peschiera del Garda, 18-19/12/2017.
- Conference: Transbronchial cryobiopsy in diffuse parenchymal lung disease – 4th edition. Ravenna, 10-11/10/ 2017. Presentation: “Cryo-TBB side effects”.
- Conference: Transbronchial cryobiopsy in diffuse parenchymal lung disease – 4th edition. Ravenna, 10-11/10/2017. Presentation: “Multidisciplinary team at work”.
- Conference: ERS (European Respiratory Society) Conference 2017. Presentation: “Challenging clinical cases: a patient with adenocarcinoma and a progressive predominant upper lobe disease”. Milano, 10/09/2017

- Conference: ERS (European Respiratory Society) Conference 2017. Presentation: "Histological aspects of UIP pattern on cryobiopsy in patients with idiopathic pulmonary fibrosis". Milan, 13/9/2017 (on Ilaria Nardi's behalf).
- Conference: Interventional Pulmonology in Nordics and Italy. Aarhus, 25/4/2017. Presentation: "Foreign bodies in the airways".
- Conference: ERS course PneumoTrieste. Presentation: "practical work". Trieste, 3-5/4/2017.
- Conference: Transbronchial cryobiopsy in diffuse parenchymal lung disease. Ravenna, 27-28/10/2016. Presentation: "MDD Corner I. Case discussion"
- Conference: Transbronchial cryobiopsy in diffuse parenchymal lung disease. Ravenna 27-28/10/2016. Presentation: "Standardization and complications of cryo-TBB"
- Conference: PneumoTrieste. Trieste, 11-13/4/ 2016. Presentation: "MDD team at work"
- Conference: PneumoTrieste. Trieste, 11-13/4/2016. Presentation: "Miscellaneous interstitial pneumonia with autoimmune features (IPAF)"
- Conference: International School for Interstitial Lung Disease (ISILD). Erice, 9-11/12/ 2015. Presentation: "Guideline recommendations for gastroesophageal reflux treatment in IPF: the sound of distant thunder. CONS"
- Conference: 9° Corso della Scuola Internazionale di Medicina dello Sport del Centro Ettore Majorana di Erice. Erice, 15-18/10/2015
- Conference: Transbronchial cryobiopsy in diffuse parenchymal lung disease. Ravenna, 8-9/9/2015. Presentation: "Clinical ground round"
- Conference: PneumoTrieste. Trieste, 13-15/4/2015. Presentation: "Clinical Ground Round. Clinical cases"

#### **Chairman at conferences (national and international):**

- Chair of course "Biopsy techniques and pathology of ILD". ERS online course 21 november – 12 december 2019
- Chair of II SESSION: CLINICAL/RADIOLOGIC/PATHOLOGIC CORNER at Tranbronchial cryobiopsy in diffuse parenchymal lung disease – 7<sup>th</sup> Edition (COURSE HELD AS LIVE WEBINAR VIA MULTIMEDIA PLATFORM). 18/09/2020
- Chair of the E-Poster Session entitled "Real life in the field of idiopathic pulmonary fibrosis: treatments and registries" at ERS (European Respiratory Society) Conference 2020, Virtual, 4-9/9/2020
- Chair of 3<sup>rd</sup> session "clinical corner" at Tranbronchial cryobiopsy in diffuse parenchymal lung disease – 6<sup>th</sup> Edition. Florence, 13/11/2019
- Chair of 1<sup>st</sup> session "Le pubblicazioni scientifiche: articoli e abstract" at Forum Giovani Pneumologi. Florence, 13/11/2019. Chair of VIII session Live at Corso teorico-pratico PID Pneumopatie Infiltrative Diffuse. Forlì, 25-27/6/2019.
- Chair of Thematic Poster Session entitled "Granulomatous disorders: pathogenesis, epidemiology and clinical issues" at ERS (European Respiratory Society) Conference 2018, Madrid, 30/9/2019
- Chair of 1<sup>st</sup> session at conference: Transbronchial cryobiopsy in diffuse parenchymal lung disease. Milan, 1-2/10/2018.

- Chair of Thematic Poster Session entitled “CTD-ILD and hypersensitivity pneumonitis: mechanistic insights and prognostic markers” at ERS (European Respiratory Society) Conference 2018, Paris, 15-19/9/2018.
- Chair of session entitled “Seduta endoscopica in videoconferenza” at “Corso teorico-pratico PID Pneumopatie Infiltrative Diffuse”. Forlì, 26-28/6/2018
- Chair of session entitled “Pathogenetic corner I” at “The pathogenesis of COPD and IPF: distinct horns of the same devil? International workshop”. Florence, 3-5/5/2018.
- Chair of session “Il rapporto medico-paziente” at “Respirare e comunicare: cosa dobbiamo ancora imparare. My new life chapter 2”. Forlì, 15-16/3/2018.
- Chair at conference: “International Summit of Interstitial Lung Disease (ISILD)” – Erice, 9-12/12/2017. Session entitled “Translational stream: metagenomics/other biomarkers in IPF”
- Chair at conference: “IPF in practice. Personalizzare l'algoritmo terapeutico”. Ravenna 9-10/11/2017. Session entitled “Aspetti psicologici”
- Chair at conference: “Transbronchial cryobiopsy in diffuse parenchymal lung disease – 4<sup>th</sup> edition”. Ravenna 10<sup>th</sup> – 11<sup>th</sup> October 2017. Session entitled “Multidisciplinary team at work (Rising Stars)”.
- Chair at conference: ERS (European Respiratory Society) Conference 2017, Milan. Oral presentation session entitled “From idiopathic pulmonary fibrosis (IPF) to rare diseases”. Milan, 13/9/2017.
- Chair at conference: ERS (European Respiratory Society) Conference 2017, Milan. Thematic poster session entitled “IPF: from the bench to the bedside”. Milan, 10/9/2017.
- Chair at conference: “Transbronchial cryobiopsy in diffuse parenchymal lung disease”. Ravenna 27-28/10/2016. Session entitled “Cryo-TBB in DPLD II. Cryo-TBB movies”.
- Chair at conference: ERS (European Respiratory Society) Conference 2016, London. Thematic Poster Session entitled “IPF: from pathogenesis to treatment I”. London 3-7/9/2016.
- Chair at conference: ERS (European Respiratory Society) Conference 2015, Amsterdam. Thematic Poster entitled “Interstitial lung diseases II”. Amsterdam, 29/9/2015.
- Chair at conference: Fibrosi Polmonare Idiopatica. Session entitled “ERS – IPF statement”. Forlì 9-11/2/2016.

#### Conferences Organizing/Scientific committee:

- Corso ECM FAD “pneumopatie fibrosanti, discussione interattiva tra esperti”. Seminario organizzato in formato webinar. Date: 25 settembre 2020, 23 ottobre 2020, 20 November 2020
- Conference “Pneumopatie fibrosanti: discussione tra esperti”. Forlì, online dal 6.3.2020 al 29.5.2020.
- XLIV Congresso Nazionale AIPO – Congresso Nazionale FIP. Firenze 13-16/11/2019.
- “The pathogenesis of COPD and IPF: distinct horns of the same devil? International workshop”. Firenze 3-5/5/2018.

#### Poster communication (as presenting author):

- “Cryobiopsy in the diagnosis of diffuse parenchymal lung diseases: diagnostic strategy and complications in 699 patients”. C. Ravaglia, S. Tomassetti, A. Dubini, S. Piciocchi, V. Poletti. Presented at ERS International Conference, Paris 2018.

- “Cryobiopsies are diagnostic in pleuroparenchymal fibroelastosis and airway-centered fibroelastosis”. Kronborg-White S, Ravaglia C, Bendstrup E, Poletti V. Oral presentation at “The pathogenesis of COPD and IPF: distinct horns of the same devil? International workshop”. Florence, 3-5/5/2018.
- “Cryobiopsy in the diagnosis of diffuse parenchymal lung diseases: diagnostic strategy and complications in 699 patients”. Ravaglia C, Dubini A, Tomassetti S, Piciucchi S, Gurioli C, Gurioli C, Poletti V. Oral presentation at “The pathogenesis of COPD and IPF: distinct horns of the same devil? International workshop”. Florence, 3-5/5/ 2018.
- “Histological aspects of UIP pattern on cryobiopsy in patients with idiopathic pulmonary fibrosis”. Oral presentation at ERS (European Respiratory Society) Conference, Milan Milan, 13/9/2017.
- “Cryobiopsy during medical thoracoscopy”. Viglietta L, Pavano C, Ravaglia C, Gurioli C, Tomassetti S, Piciucchi S, Dubini A, DiMaria GU, Gurioli C, Fuso L Poletti V. Oral presentation at 19th WCBIP/WCBE World Congress, Florence 8-11/5/2016.
- “Complications and mortality of transbronchial lung cryobiopsy and surgical lung biopsy in interstitial lung diseases”. Ravaglia C, Tomassetti S, Casoni GL, Gurioli C, Piciucchi S, Gurioli C, Sanna S, Dubini A, Poletti V. Presented at ERS International Conference, Amsterdam 2015.
- “BAL findings in desquamative interstitial pneumonia (DIP) and other idiopathic interstitial pneumonia (IIP)”. Ravaglia C, Tomassetti S, Casoni GL, Gurioli C, Gurioli C, Romagnoli M, Piciucchi S, Dubini A, Chilosi M, Poletti V. Presented at ERS International Conference, Munich 2014.
- “Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series”. C. Ravaglia, C. Gurioli, M. Romagnoli, G. Casoni, S. Tomassetti, C. Gurioli, V. Poletti. Presented at ERS International Conference, Barcelona 2013.
- “(18)F-FDG positron emission tomography/computed tomography and pulmonary function in sarcoidosis”. Ravaglia C, Gurioli C, Romagnoli M, Casoni GL, Tomassetti S, Gurioli C, Poletti V. Presented at ERS International Conference, Barcellona 2013.
- “Sarcoidosis is a frequent benign cause of lymphadenopathy in neoplastic patients”. C. Ravaglia, C. Gurioli, G. Casoni, M. Romagnoli, S. Tomassetti, C. Gurioli, V. Poletti. Presented at ERS International Conference, Vienna 2012.
- “Sarcoidosis and autoimmune thyroid disease”. Ravaglia C, Gurioli C, Casoni GL, Romagnoli M, Tomassetti S, Gurioli C, Poletti V. Presented at ERS International Conference, Vienna 2012.
- “Is medical thoracoscopy indicated in the management of multiloculated and organized thoracic empyema?”. Ravaglia C, Gurioli C, Tomassetti S, Casoni GL, Romagnoli M, Gurioli C, Poletti V. Presented at ERS International Conference, Amsterdam 2011
- “Familial idiopathic pulmonary fibrosis and genetic anticipation”. Ravaglia C, Tomassetti S, Casoni GL, Romagnoli M, Gurioli C, Gurioli C, Piciucchi S, Poletti V. Presented at ERS International Conference, Amsterdam 2011
- “The diagnostic role of rapid on site cytologic examination (ROSE) of bronchoalveolar lavage in acute lung injury/acute respiratory distress syndrome”. Ravaglia C, Marinou A, Gurioli C, Romagnoli M, Casoni GL, Tomassetti S, Gurioli C, Corso RM, Poletti V. Presented at ERS International Conference, Barcellona 2010

#### Teaching, tutorship, supervision, university

- Insegnamento presso Università di Ancona al Master di I/II livello in Pneumologia Interventistica; modulo didattico di “BAL: tecnica, indicazioni e risultati”. Facoltà di Medicina e Chirurgia. 2020
- Co-relatore: Novembre 2020, Dr Corrado Ghirotti, tesi di specializzazione in Malattie dell'Apparato Respiratorio dal titolo “Complicated Empyema: an alternative treatment instead of surgery”

#### Other scientific activities

- Member of ERS (European Respiratory Society) – College of experts (from 2017 onwards) and Reviewer of ERS Clinical Training Fellowship
- In 2011 participating in the research project “Bronchoalveolar lavage cellularity in hypersensitivity pneumonitis identifies patients with survival similar to IPF” (supported by



- NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London).
- 2012 participating in the research project "Genetic profile of Familial Pulmonary Fibrosis: tightening up the links to lung cancer biology" (collaboration with Oncology and Biology Labs – IRST Meldola, Italy).
- Member of the Global IPF Collaborative Network (University of Colorado, USA) and participating in the research project: "Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis"
- 2016-2017 member of the "IPF PROJECT CONSORTIUM"
- From 2017 onwards participating in the research project "ICED-SLB" (collaboration with 1) Vanderbilt University School of Medicine, Nashville, TN, USA; 2) Ohio State University, Columbus, OH, USA; 3) Universitat Autònoma de Barcelona, Barcelona, Spain; 4) Mayo Clinic, Rochester, MN, USA
- Consulente esperto per EMA (European Medicines Agency) a partire da 14.01.2020 (meeting Amsterdam 22.1.2020)
- Expert Panelist of the Task Force for the Practice Guidelines 2020-2021 on "Transbronchial cryobiopsy and surgical lung biopsy in interstitial lung diseases" of the European Respiratory Society
- Reviewer of the 2020-2021 ATS/ERS Clinical Practice Guidelines of "Pulmonary Alveolar Proteinosis: Diagnosis and Management" of the European Respiratory Society

#### Attività pratiche e specifiche competenze professionali

- Piena autonomia nell' attività clinica assistenziale consistente in attività broncoscopica (sia broncoscopia rigida che flessibile), comprensiva di turni di pronta reperibilità endoscopica (circa 8-10 turni/mese), attività specialistica ambulatoriale, attività di consulenza pneumologica per tutte le U.O. dell'Ospedale di Forlì, attività di Day Service e Day Hospital.
- Procedure eseguite: broncoscopie rigide sia diagnostiche che operative (disostruzioni e posizionamento di protesi tracheo-bronchiali), biopsie/aspirati linfonodali mediastinici (TBNA, EBUS-TBNA, EUS-FNA), biopsie transbronchiali con criosonda (di cui il centro di Forlì è pioniere nonché detentore della maggiore casistica a livello internazionale con 699 casi pubblicati ed oltre 1000 casi eseguiti), broncoscopie flessibili, biopsie transbronchiali con sonda convenzionale, con EBUS radiale, lavaggi broncolaveolari, broncolavaggi e broncospirazioni, toracoscopie mediche, lavaggio polmonare totale, posizionamento di valvole endobronchiali nel trattamento dell'enfisema polmonare.
- Attività specialistica ambulatoriale e di Day Service e Day Hospital dedicata alle Malattie rare Polmonari, tra cui prevalentemente le Pneumopatie Infiltrative Diffuse, per l'area Vasta Romagna con bacino d'utenza nazionale (circa 75% di pazienti extra regione). Il centro è riconosciuto come centro di riferimento per le malattie rare polmonari sia a livello Regionale (delibera Regione ER del 09/2017), che internazionale (rete europea delle malattie rare polmonari ERN-LUNG, dal 2016).
- Referente dell'ambulatorio AIMART (Ambulatorio Interstiziopatie e Malattie Rare e Trapianto) presso UO di Pneumologia Ospedale GB Morgagni
- Attività come medico di reparto presso la degenza ordinaria della U.O. di Pneumologia dell'ospedale GB Morgagni di Forlì con casistica comprendente tutti gli ambiti pneumologici (incluse: oncologia, infettivologia e tubercolosi, insufficienza respiratoria e ventilazione non invasiva, BPCO, Asma, pneumopatie infiltrative diffuse).
- Attiva partecipazione ad attività multidisciplinari per l'oncologia polmonare (Gruppo Interdisciplinare Pneumo-Oncologico GIPO).
- Attiva partecipazione a meeting settimanali sulle malattie rare polmonari (MDT ILD Pneumologia di Forlì)
- Referente del PDTA per le pneumopatie infiltrative diffuse per l'Azienda Area Vasta Romagna (dal 2019 ad oggi)
- Referente per la pneumologia nel gruppo di lavoro in Reumatologia per la stesura del PDTA su Artrite Reumatoide per l'Azienda Area Vasta Romagna (dal 2019 ad oggi)

#### Collaborazioni con enti o istituti di ricerca

- USA: Mayo Clinic, Rochester, MN (Prof. J.H. Ryu); Mayo Clinic, Scottsdale, AZ (Prof. T.V. Colby); IPF Global collaborative IPF network, Denver, CO (Prof. D. Schwartz); UCSF, San Francisco, CA (Prof. B. Ley e Prof. H. Collard).
- UK: Royal Brompton Hospital, London (Prof. AU Wells)
- Germania: Essen Klinikum Universitat Pneumologie (Prof. U Costabel)
- Danimarca: Aarhus University (Prof. V Poletti and Dr E Benstrup)

## Attività di volontariato

- From 2009 onwards, member of AMMP (Morgagni Lung Diseases Association), an association that promotes training and information on health in the local community, especially in pulmonology, supports research and teaching programs in the field of rare diseases.
- From 2011 onwards, I participate in the AMMP School Project in collaboration with qualified psychologists that addresses the primary schools students, with the aim of sensitizing children in the prevention of lung diseases, making them aware that a correct style of life will make them healthy and better.